call. Officer everyone Thank Officer have from are you, morning, Financial Jeff. Nicholas Dr. Good and today’s Celsion’s Medical our and you Borys, Jeffrey Chief Church, whom you for With heard. just me joining thank Chief
As we update on opportunity and to you questions. progress our have to your to pleased the answer are always, very
Now, call reminding Annual Shareholder meeting joining shareholders will of that consider the I let week our the Tuesday us you Westin for me encourage held to start New would Hotel of can. Princeton, this by to on in XXXX at Meeting you be like next Jersey, record if all
person always, brief closes, few our month a with held pleasure call great see have it’s we Since deal. meet a little much you but relatively call end you, a redundant perhaps and year repeating. you to a in will to and as ago, be is are just because there If we in whenever on great conference over today’s possible worth
study, with today that’s first when promising timely liver start X of to Number study points me very of our trial sufficient call, analysis XXXX. of a pivotal our let have unmet of XX full the objectives, by a March and of ensures the important focus the ThermoDox, this and of rate entered oncology newly gene both top treatment a control and operationally OPTIMA cancer an events our investors development immunotherapy arm advanced of balance I the cash GEN-X And we very up year. where for ended the X/X X will trial ovarian need patients. in in OPTIMA Phase including cancer to runway end OVATION of as data diagnosed XX to strong in conserves enrollment this diagnosed over our to clinical mediated Phase medical months trials, in line reminds two the the year from in with remaining Celsion we importantly of study, primary first in number the two, started be year you largest II number four key remind Celsion a the cash and newly the and more the one, achieve the So, patients the consider worth you, and tight of sheet the cohort made call that II initiation results OVATION study in from in arm interim X the and
if should our to XXXX, the point us. over financial at worth behind of into flow three add operating NOLs, XXXX. are Celsion be be pursuing add sale news have thinking operating of which to or about our means before should from And OPTIMA to expectation including non-dilutive key our into the Investors net third The in X consider, losses course two of well point developments we now the taking to of to advance. steady the you could is trials resources, the and company study continue XXXX run-rate quarters well Phase results which will
in will speak call. later to this in more the Now, detail Jeff
are very full That’s timely providing focus efficient to points, strategy commitment of interim inflation balance shareholder Phase that development a with and strong enrollment ensuring key cash critical utilization, financing pleased first of We X on runway client. clinical study developments of the and goals including steady a efficacy sheet tight analysis, XXXX to our achievement value. a focuses flow and in news operationally the
heat in radiofrequency implies our beginning patient like to drug, a formulation study. know, is with greater in X the liposomal XX X studies a a the investigation with lead review study minimum in Now, on ThermoDox. tumors X I than centimeters, minutes for would a doxorubicin, called the less you centimeters clinical of than our ThermoDox, administered ablation, population Phase being as sensitive with combination in technology OPTIMA evaluated of as name
impact patient a we carcinoma, product. is XXX The of never RFA of years. primary study to reached followed liver for and X.X the in XX% this HEAT quality years in on combined of on XX control hepatocellular XX group. for the cancer ThermoDox. minutes Median and countries for type to being zones X A treat correctly for is minimum time across represents to protocol population time of over just markets up XXX-patient global when is years RFA was as centimeter overall the a XX X Now, application than the prior and our that our that or based survival. with to that’s survival the after intent more the arm trial in better survival months, treatment X.X it improvement of group is call from was median XX% greater The HCC the significant conducted lesions study, XX than in a subgroup is all death thesis will over understanding
cured. Our the investigators administered be excited potential properly to with RFA about are results of dose that the has ThermoDox that concluded the single
We have been this conferences multiple over of presenting number medical narrative the last at years.
In for combining addition standardized in of thesis minimum been our with a survival to models. tested has XX ThermoDox observations, preclinical the minutes for computational RFA and
to Our of XXXX in in greater and including alone. in Journal Data each reviewed DMC plus in survival. includes our other review for The RFA first and from longer X study in cover multiple Monitoring doxorubicin unanimously potential than its minimum was basis Committee is or the of things, April, sites by on community These compliance tumor supporting assessment year administered journals, bidding medical concentration, conclusion every integrity validated the X with reviewed study recommended was met has publications schedule that in significant that according peer was the has continued In safety unblended for Independent OPTIMA the the cancer effective overall with this Celsion’s the It the among for and in trial greater lesion specified treatment potential the for our the research April, in past based RFA of research February. the study the the XXXX rehypothesize the premise to analyses target their the the of published of been XX% early support XXXX. to protocol more not ensuring data clinical OPTIMA of survival journals. and benefit the Hyperthermia and randomized virtually properly surrounding that DMC and patients been have respect time. Recommendation combining readout. tissue through data Manuscripts improvement its data ThermoDox the HEAT analysis heating of heated,
to blinded in PSS no the that found be importantly, in acceptance so with far continue point is in remains and in In want this this emphasize consistent study subgroup in population ThermoDox’s that intent the progression-free treating that very the showed performance ThermoDox RFA will be can we encouraging the believe far We benefit intent blinded at that in and study study learned the HEAT the I and again. the view benefit study. to can PFS is with blind We finding as properly nevertheless HEAT with so specifically. we that survival subgroup treat in definitive and in population administered consistent to to the addition drawn population to in conclusion was the OPTIMA survival the blinded population progression-free treat and HCC. that the study patient learned for the showed the see
of for of median conducted lesion population want overall In analysis months. new repeat XXX death I in XXXX, the the to X we terabytes arm different in some are which population in call last an of now an to HEAT independent of treat from those Director single data just months, provided with intent than comments that’s from HEAT to than at greater Celsion. Institutes to Interventional saw of National the XX treatment XX study Oncology, we the of equal the where last the discussed I request March patients improvement from greater Now, and a call, survival study, to time who then Health they
evaluated. patients lesion patients the lesions were So this population, with in study single all single
of RFA study Korea. world. improvement RFA Seoul, RSNA Conference, study This selection at XXXX, North and X with the in annually selected two in it’s Society is of Phase study Tak X in was the part the HEAT evaluating of conducted Association’s ThermoDox Annual Young of abstract manuscript leading Presidential Won in luxury Scientific the Meeting in in author Korean times February combination too that of not conference that’s in the by true South X conferences with RFA significant RFA identical HEAT identical Radiological combined XXth concluded the looked Dr. the by While of largest an was virtually company’s were the study, More for of and alone. discussing America presentation when cohorts, evaluation Cancer RFA NIH Liver medical These heating resulted one is the of statistically longer December the presented overall alone, recently ThermoDox a virtually findings survival. XXXX, with ThermoDox, of with
data of the So when overall investigators NIH’s look HEAT the Tak’s colleagues the medical survival interest the improvement results study at you multiple presentation. are Dr. study in this, showing in their at HEAT in and an to bringing all conferences, on interest
all also you OPTIMA that Street XX approved study this globe does. reviewed authorities all America and said can’t of help the medical If will clearly Europe, the regulatory conclude where in one I note it including time, markets, Asia the major from look at the this, is I that North protocol. Wall HCC across but community before, gets rare as you before and
strategy interactions. Our on based these is regulatory
support revenue other patients been market for provides designation in drug received and of X to and and We for granted Canada, respectively Philippines, both market United to designation number for cancer designed and Taiwan, Europe, the orphan fast-track ThermoDox sufficient OPTIMA in have primary XX South these the things from Korea, each U.S., also filings China, launch which U.S., Vietnam. major in extends country the priority Malaysia States Thailand, study years ThermoDox has In the registration has among Europe, liver exclusivity review. enroll markets. and
as many can trial, a Additionally, in that’s the for direct ongoing is Borys OPTIMA trial Administration the without Phase China the the the informed need me, applications. filing as study the CFDA, and the basis file Dr. foreign X could basis regulatory data prior approval or so China required to from if serve company which U.S. Celsion, successful, that’s Europe, for is Drug a Food in serve for and currently
originating XXX,XXX launch in financial this its departure in Celsion provide China would most globally than patients and and HCC of originally conduction course but While earlier accelerate ThermoDox China approved, is perhaps significant significantly with filing regulatory diagnosed from the market China represents each XX% deal if to newly opportunity China approximately allow for of for in anticipated. year.
Practice, on have and regard high class to protocol research internationally management Good the Clinical contract execution quality world to compliance, we recognized with the ensure trial teams analytics. data data organizations Now, itself and side, engaged adherence ICH
redundant a highly market. have in supporting organizations and gross high the and chain reliable all supply We world of also contract of registered proven producing margins regions of capable with manufacturing were ThermoDox X the regardless
Now, GEN-X. I want to turn to
and last plasmid technology system gene-mediated I developed system is which fight cytokine, nanoparticle As is nanoparticles these discussed even plasmid cells for or synthetic the production to body cavity agent immune each cell on biopharmacy cavity locally immunotherapy, malignancy. a of over created into administered IL-XX, metabolic a GEN-X TheraPlas into proprietary month, the turning the body’s platform When into our a a peritoneum interleukin-XX. or local the transvect a TheraPlas. surgical incorporated is potent the interleukin-XX. sustained removal GEN-X’s coded for take surrounding of called machinery, the our mass, like The IL-XX anticancer or tumor the by invade recruits or a DNA active little delivery bladder
we studying GEN-X is first cancer. know is are ovarian The as for you indication
this diagnosed surviving less there XX% years. with than For chance is cancer, patients of a X newly
for signs major The weekly recurrent debulking of cancer X have newly goal I is spread ovarian is is the by ovarian in to stages previous GEN-X advanced GEN-X clinical both of chemotherapy our mass study. when monotherapy GEN-X regimen been added results. study in disease, OVATION plus the is The reasons a then the cancer neoadjuvant study, clear diagnosis clinical chemotherapy in this One surgery. shrinking up drying surgical disease Xb cycles in in newly with evaluated patients Phase throughout made particularly importantly, combination as is of populations the the outcome we I tumor activity trials promising surgery In has patients patient interval benefit fluids escalation GEN-X X, the cancer in the of the that this dosing however, standard chemotherapy X the followed region. used OVATION chemotherapy pelvic demonstrated In neoadjuvant and when Most to diagnosed trial, in accompanying improve and with and showing [indiscernible]. and by followed patients. diagnosed by of advanced
include I very findings. would findings say following this Our the from this in study include and impressive population
PFS up significant dose with highest oversight clear milligrams and the any GEN-X. find toxicities neoadjuvant dose. among the findings clinical toxicities XXX% XX environment First, meter tumor able to dose an limiting or investigators patients. tested in in PFS importantly patient remove patients the and chemotherapy in of the bioactivity GEN-X with in associated XX% are XX% The changes all were partial appear the in treated response this over be is plus following as to The a XX outcome visible is demonstrated is per Historically, at tumor included highest patients, resection committee, surgeons efficacy XX no safe this square. to RX months. approximately and in complete completely is months. known dose-dependent The to micro the did prone PFS the of Distinct immune projected be that’s population findings patients clinical of treated in immunological not result. There protocol. DSMB,
cohort X/X treatment It’s Phase called XXXX, to II Now, a of treat clinical November study. the plan of randomized per submission was We last dose the was highest GEN-X approximately an OVATION last arm we dose based the open the by these that’s X the study. on in the – announced findings with dose the patients previous square, XXX FDA to in that that first the greater label for localized cancer. treated the treated, milligrams protocol XX% meter trial study at ovarian the last than XX% in
criteria patients. XXX with the with start square, dose the per to X continuation will are the up portion study The followed the of as addition. XXX selected prior by major I in entry So, protocol one the milligrams OVATION in same meter treatment Phase study and a
of debulking will additional a to Following this up continue receive maintenance doses surgery, be will intraperitoneal GEN-X, X to patients therapy.
a is effect hypothesis surgery beneficial stimulation immune of that progression. the delaying Our system further provide by may after continuous
enrollment the XXXX. portion initiating Before a this portion open in away X in to This the first we weeks we X, X by and anticipate Phase expect study to the an XXXX. of data Phase throughout June Phase few initiate periodically be just of label study quarter report will expect
GEN-X’s are PIs. as our we the potential Now, excited with
highlighted in in form – associated of designed New March presentation investor to IL-XX Premal Treatments GEN-X entitled Dr. an Horizons and with protein novel and the event presentation the Thaker, for York. presented deploy Ovarian approach without Thaker’s our program example, lead As a at toxicities development from OVATION the the an outline Cancer: GEN-X principal made XXXX, New is study. a the Dr. results recombinant investigator
consistent Our changes systemic levels no cytokines and little and IL-XX GEN-X the systemic its in immunological anticancer of peritoneal toxicities. circulation with with increase changes ability presentation noted downstream of to
If you are on be our found interested, presentation can website.
Now, before say our I not like XXXX expect to be an I CFO, important, call year. to transformational to turning would the over that if
efforts backed way, with said our excellence operational progress call, I focused our ThermoDox make for last development capital management. on is by Gen-X think and in financial year. responsible achieved I One will significant this our and
to that financials, to will discuss with Now, Jeff. now turn Jeff? the our I call over
